Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benlysta And Fampyra Fail to Make Headway As IQWiG Tightens Comparator Screw

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany’s health technology evaluator’s rejection of GSK’s Benlysta and Biogen Idec’s Fampyra could force companies to design separate trials for authorization and HTA assessment.

You may also be interested in...



German End-Of-Year Figures Highlight Potential Danger To Pharma R&D

The German pharmaceutical market has dealt impressively with the government’s cost-cutting measures, but they are beginning to take their toll on R&D and innovation, industry maintains.

German Reimbursement Dossiers Look Trickier After Rejection Of Eisai’s Fycompa

Eisai’s novel epilepsy drug Fycompa will have a tough time qualifying for reimbursement in Germany after the cost-effectiveness regulator IQWiG said the manufacturer did not stick to HTA guidance on comparator selection.

European HTA Highlights: IQWiG Focuses On Indications, Benefits; NICE Still Obsessed With Cost Controls

Germany’s IQWiG is concentrating on product benefits in its reviews, though is still expecting carefully tailored studies from sponsors. But industry’s concern in England continues to focus on NICE’s obsession with saving the NHS money – meaning pharma must make innovation cheaper to succeed.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS074116

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel